Vanguard Personalized Indexing Management LLC Has $1.24 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,064 shares of the company’s stock after buying an additional 326 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Neurocrine Biosciences were worth $1,235,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Mather Group LLC. acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $26,000. RFP Financial Group LLC boosted its position in shares of Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after purchasing an additional 149 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth approximately $30,000. Finally, New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences in the first quarter valued at approximately $32,000. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on NBIX shares. Wedbush reiterated an “outperform” rating and issued a $152.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th. Jefferies Financial Group boosted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Finally, Oppenheimer boosted their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $162.20.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at $5,499,554.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Ingrid Delaet sold 273 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the sale, the insider now owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,798 shares of company stock worth $10,676,096. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $118.35 on Monday. The company has a market capitalization of $11.91 billion, a P/E ratio of 32.60 and a beta of 0.37. The company’s 50-day moving average is $138.49 and its 200 day moving average is $138.21. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The company had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same period last year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 30.4% compared to the same quarter last year. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.